“The main feature of this vaccine is the specific development for the adult and elderly population,with a high level of immunosenescence. Consequently, a specific antigen, the F protein, was combined with an adjuvant system, in particular the as01e system which was designed to increase the immune response and confer greater protection to this particularly vulnerable population.” This is what was stated by Marta Vicentini, RSV medical lead of GSK, on the occasion of the press conference, organized in Rome by GSK, on the respiratory syncytial virus.
What advancements have been made in RSV vaccine development for older adults and vulnerable populations?
Interview with marta Vicentini, RSV Medical Lead at GSK: Advances in Vaccination for Vulnerable Populations
Date: October 2023
Interviewer: Editor of Time.news
Editor: Thank you for joining us, Marta. It’s a pleasure to have you here to discuss the recent developments surrounding the respiratory syncytial virus (RSV) vaccine specifically designed for adults and the elderly.Can you elaborate on the unique features of this vaccine?
Marta vicentini: Thank you for having me.The main feature of our vaccine is it’s tailored development aimed at adults and the elderly who often experience a high level of immunosenescence, which means their immune responses are weaker as they age. We have designed this vaccine to target this population effectively by combining a specific antigen, the F protein, with an innovative adjuvant system, specifically the as01e system. This combination is crafted to enhance the immune response, offering greater protection to this vulnerable group.
Editor: That’s fascinating! Can you explain the importance of using the F protein in this vaccine and how the as01e system helps improve its efficacy?
Marta Vicentini: Absolutely. The F protein plays a critical role in the virus’s ability to invade host cells and provoke a strong immune response. By focusing on this specific antigen, we can elicit a more robust immune memory. The as01e adjuvant system aids in boosting the immune reaction to the vaccine, making it more effective at generating long-lasting protection for those at risk, especially older adults who may not respond as well to customary immunizations.
Editor: What implications do these advancements have for public health, especially for older populations?
Marta Vicentini: The implications are quite significant. As the global population ages, the incidence of RSV infections in adults, particularly the elderly, is a growing concern. With this vaccine, we aim to reduce hospitalizations and severe outcomes associated with RSV. Enhancing immunity in this demographic could lead to decreased healthcare costs and better overall health outcomes, significantly benefiting public health systems.
Editor: in light of these advancements, what practical advice would you offer to older adults or caregivers regarding RSV and vaccination?
Marta Vicentini: I encourage older adults and their caregivers to stay informed about RSV and consider vaccination as a proactive step in protecting their health. It’s vital to consult healthcare providers to discuss vaccination options available for RSV, especially when the vaccine is rolled out. Understanding the risks associated with RSV and ongoing updates from health authorities will empower them to make informed decisions.
Editor: What role do you see for GSK in the future of RSV vaccination and research?
Marta Vicentini: GSK is committed to leading efforts in RSV vaccine development and contributing to public health through innovative solutions. Our focus will remain on advancing research and understanding this virus better to ensure we’re meeting the needs of vulnerable populations. We are also dedicated to collaborating with health authorities and other organizations to facilitate awareness and accessibility of this importent vaccine.
Editor: Thank you, Marta, for sharing these essential insights into RSV vaccination. It’s been an enlightening conversation that I’m sure will resonate with our readers.
Marta Vicentini: Thank you for having me. I appreciate the opportunity to share this critical information, and I hope it encourages everyone to take RSV seriously, particularly in older populations.